NGS is primarily applied in advanced non-squamous NSCLC, where tumor NGS testing is routinely recommended owing to the presence of numerous actionable genetic alterations, including EGFR, ALK, and ROS1, which can be targeted with specific therapies. Here, ALK is linked to non-small cell lung carcinoma.